Curanex Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering
Curanex Pharmaceuticals (NASDAQ:CURX), a developmental stage pharmaceutical company focused on botanical drugs for inflammatory diseases, has announced the pricing of its initial public offering of 3,750,000 shares at $4.00 per share.
The IPO is expected to raise $15 million in gross proceeds before deducting underwriting costs. Trading will commence on August 26, 2025 on the Nasdaq Capital Market. Underwriters have a 45-day option to purchase up to 562,500 additional shares.
Proceeds will fund the development of their lead product Phyto-N for ulcerative colitis, conduct FDA-required toxicology studies, prepare an IND application, and provide working capital. Dominari Securities leads the underwriting, with Pacific Century Securities and Revere Securities as co-underwriters.
Curanex Pharmaceuticals (NASDAQ:CURX), società farmaceutica in fase di sviluppo specializzata in farmaci botanici per le malattie infiammatorie, ha annunciato il prezzo della sua offerta pubblica iniziale di 3.750.000 azioni a 4,00 USD per azione.
L'IPO dovrebbe raccogliere 15 milioni di dollari di proventi lordi prima delle commissioni di sottoscrizione. Le azioni inizieranno a essere negoziate il 26 agosto 2025 sul Nasdaq Capital Market. I sottoscrittori hanno un'opzione di 45 giorni per acquistare fino a 562.500 azioni aggiuntive.
I proventi serviranno a finanziare lo sviluppo del prodotto principale Phyto-N per la colite ulcerosa, a condurre studi tossicologici richiesti dalla FDA, a preparare una domanda IND e a fornire capitale operativo. Dominari Securities guida la sottoscrizione, con Pacific Century Securities e Revere Securities come co-sottoscrittori.
Curanex Pharmaceuticals (NASDAQ:CURX), compañía farmacéutica en etapa de desarrollo centrada en medicamentos botánicos para enfermedades inflamatorias, ha anunciado el precio de su oferta pública inicial de 3.750.000 acciones a 4,00 USD por acción.
Se espera que la OPV recaude 15 millones de dólares en ingresos brutos antes de deducir los costos de la colocación. Las acciones comenzarán a cotizar el 26 de agosto de 2025 en el Nasdaq Capital Market. Los suscriptores disponen de una opción de 45 días para comprar hasta 562.500 acciones adicionales.
Los fondos financiarán el desarrollo de su producto principal Phyto-N para la colitis ulcerosa, la realización de estudios toxicológicos exigidos por la FDA, la preparación de una solicitud IND y proporcionarán capital de trabajo. Dominari Securities lidera la sindicación, con Pacific Century Securities y Revere Securities como co-suscriptores.
Curanex Pharmaceuticals (NASDAQ:CURX), 염증성 질환을 위한 식물 유래 약물 개발에 주력하는 개발 단계의 제약사로서, 3,750,000주의 신규 상장(IPO)을 주당 4.00달러로 공시했습니다.
이번 IPO는 인수 비용을 공제하기 전 총 1,500만 달러의 자금 조달을 기대하고 있습니다. 주식은 2025년 8월 26일 나스닥 캐피털 마켓에서 거래를 시작합니다. 인수단은 45일간 최대 562,500주를 추가로 매수할 수 있는 옵션을 보유합니다.
조달 자금은 주력 제품인 Phyto-N(궤양성 대장염 치료제) 개발, FDA 요구 독성학 시험 수행, IND 신청 준비 및 운전자본 확보에 사용될 예정입니다. Dominari Securities가 주간사이며 Pacific Century Securities와 Revere Securities가 공동주간사로 참여합니다.
Curanex Pharmaceuticals (NASDAQ:CURX), une société pharmaceutique en phase de développement spécialisée dans les médicaments à base de plantes pour les maladies inflammatoires, a annoncé le prix de son offre publique initiale de 3 750 000 actions à 4,00 USD par action.
L'introduction en bourse devrait permettre de lever 15 millions de dollars de produits bruts avant déduction des frais de souscription. Les titres commenceront à être négociés le 26 août 2025 sur le Nasdaq Capital Market. Les teneurs de livres disposent d'une option de 45 jours pour acheter jusqu'à 562 500 actions supplémentaires.
Les fonds serviront à financer le développement de leur produit principal Phyto-N pour la rectocolite hémorragique, à réaliser les études toxicologiques exigées par la FDA, à préparer une demande IND et à fournir des fonds de roulement. Dominari Securities dirige le placement, avec Pacific Century Securities et Revere Securities comme co-animateurs.
Curanex Pharmaceuticals (NASDAQ:CURX), ein Pharmaunternehmen in der Entwicklungsphase, das sich auf botanische Arzneimittel gegen entzündliche Erkrankungen konzentriert, hat den Preis seiner Initial Public Offering über 3.750.000 Aktien auf 4,00 USD je Aktie festgelegt.
Die IPO soll vor Abzug der Emissionskosten 15 Millionen US-Dollar Bruttoerlös einbringen. Der Handel beginnt am 26. August 2025 am Nasdaq Capital Market. Die Konsortialbanken haben eine 45-tägige Option zum Erwerb von bis zu 562.500 zusätzlichen Aktien.
Die Erlöse sollen die Entwicklung des Leitprodukts Phyto-N für Colitis ulcerosa finanzieren, toxikologische Studien nach FDA-Anforderungen durchführen, einen IND-Antrag vorbereiten und Betriebskapital bereitstellen. Dominari Securities führt das Underwriting, Pacific Century Securities und Revere Securities sind Co-Unterwriter.
- IPO expected to raise $15 million in gross proceeds for product development
- Lead product candidate Phyto-N targets the significant ulcerative colitis market
- Clear allocation of funds for specific development milestones including IND application
- Strong underwriting support with three investment banks involved
- Early-stage developmental company with no approved products
- Relatively small IPO size may limit institutional investor interest
- Potential dilution risk from underwriters' option for additional shares
- Significant regulatory hurdles ahead with FDA approval process
Insights
Curanex raises $15M in IPO at $4/share to fund development of botanical drug Phyto-N for ulcerative colitis.
Curanex Pharmaceuticals has completed its initial public offering, raising
The IPO structure includes a 45-day option for underwriters to purchase an additional 562,500 shares, potentially increasing the total raise. Trading begins immediately on the Nasdaq Capital Market under ticker CURX, with the offering expected to close August 27th.
The funding allocation is clearly defined with four specific purposes: (1) advancing Phyto-N development, (2) conducting FDA-required toxicology and pharmacokinetic studies, (3) preparing and submitting an Investigational New Drug application, and (4) general working capital.
As a developmental-stage company with no marketed products yet, this capital infusion provides Curanex runway to progress through critical regulatory milestones. The
Jericho, New York, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) ("Curanex" or the "Company"), a developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, today announced the pricing of its initial public offering (the “Offering”) of 3,750,000 shares of common stock at a public offering price of
The Company has granted the underwriters an option, exercisable within 45 days from the close of the Offering, to purchase up to 562,500 additional shares of common stock at the public offering price, less underwriting discounts and expenses. The Offering is expected to close on August 27, 2025, subject to customary closing conditions.
The Company intends to use the proceeds from the Offering for: (i) the development of our lead product candidate, Phyto-N, for the treatment of ulcerative colitis; (ii) to conduct FDA-required good laboratory practice (“GLP”) toxicology and pharmacokinetic studies for Phyto-N in ulcerative colitis, (iii) to prepare and submit an Investigational New Drug (IND) application, and (iv) for working capital and other general corporate purposes.
Dominari Securities LLC is acting as the lead underwriter for the Offering, with Pacific Century Securities LLC and Revere Securities LLC acting as co-underwriters. The Crone Law Group, P.C. is acting as counsel to the Company. Sichenzia Ross Ference Carmel LLP is acting as lead counsel to the underwriters with respect to the Offering.
A registration statement on Form S-1, as amended (File No. 333-282686) relating to the Offering was previously filed with the Securities and Exchange Commission (the “SEC”) and subsequently declared effective by the SEC on August 12, 2025. The Offering is being made only by means of a prospectus, forming a part of the registration statement. A final prospectus relating to the Offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov.
Electronic copies of the final prospectus related to the Offering may be obtained, when available, from Dominari Securities LLC, 725 5th Avenue, 23rd Floor, New York, NY 10022, or by telephone at (212) 393-4500.
Before you invest, you should read the final prospectus and other documents the Company has filed or will file with the SEC for more complete information about the Company and the Offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is a developmental stage pharmaceutical company headquartered in Jericho, New York, dedicated to discovering and developing botanical drugs for inflammatory diseases. Its lead candidate, Phyto-N, is a botanical extract from a single plant with proven anti-inflammatory properties that acts via multiple targets and mechanisms. Phyto-N has a long history of human use, having treated thousands of patients with inflammatory diseases over 30 years in China, demonstrating favorable tolerability.
The Company has validated Phyto-N's effects in animal models of six inflammatory diseases: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The primary indication is moderate to severe ulcerative colitis. The Company will advance its lead botanical drug candidate, Phyto-N, through FDA-required studies, IND submission, and into Phase I clinical trials.
For more information, visit the Company’s website at www.curanexpharma.com.
Forward-Looking Statements
All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the Company’s proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including the expectation that the Offering will be successfully completed. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the SEC.
For more information, please contact:
Curanex Pharmaceuticals Inc
Attn: Liqin Xie, Chief Operating Officer
info@curanexpharma.com.
FAQ
What is the IPO price for Curanex Pharmaceuticals (CURX) stock?
When will CURX stock begin trading on Nasdaq?
How will Curanex use its IPO proceeds?
Who are the underwriters for the Curanex (CURX) IPO?
What is Curanex Pharmaceuticals' main product candidate?
